These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 10123838

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients].
    Pensotti C, Nacinovich F, Vidiella G, Carbone E, Marin M, Di Stéfano C, Stamboulian D.
    Medicina (B Aires); 2002; 62 Suppl 2():40-7. PubMed ID: 12481488
    [Abstract] [Full Text] [Related]

  • 4. Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin.
    Crane VS, Garabedian-Ruffalo SM.
    Hosp Formul; 1992 Dec; 27(12):1199-200, 1203-4, 1207-10. PubMed ID: 10122506
    [Abstract] [Full Text] [Related]

  • 5. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
    LeFrock JL, Ristuccia AM, Ristuccia PA, Quenzer RW, Haggerty PG, Allen JE, Lettau LA, Schwartz R, Appleby D.
    Eur J Surg Suppl; 1992 Dec; (567):9-13. PubMed ID: 1381644
    [Abstract] [Full Text] [Related]

  • 6. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.
    Nathwani D, Li JZ, Balan DA, Willke RJ, Rittenhouse BE, Mozaffari E, Tavakoli M, Tang T.
    Int J Antimicrob Agents; 2004 Apr; 23(4):315-24. PubMed ID: 15081078
    [Abstract] [Full Text] [Related]

  • 7. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, Taylor L, Hayman S, Shaw S, Kibbler C, Shulman R, Singer M, Wilson AP.
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [Abstract] [Full Text] [Related]

  • 8. Non-inpatient use of teicoplanin.
    Nathwani D.
    Int J Clin Pract; 1998 Feb; 52(8):577-81. PubMed ID: 10622058
    [Abstract] [Full Text] [Related]

  • 9. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A, Palau E, Puerro M, Vargas E, Picazo JJ.
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A pilot study of oral fleroxacin given once daily in patients with bone and joint infections.
    Putz PA.
    Am J Med; 1993 Mar 22; 94(3A):177S-181S. PubMed ID: 8452177
    [Abstract] [Full Text] [Related]

  • 12. [Outpatient parenteral antimicrobial therapy (OPAT) in bone and joint infections].
    Galpérine T, Ader F, Piriou P, Judet T, Perronne C, Bernard L.
    Med Mal Infect; 2006 Mar 22; 36(3):132-7. PubMed ID: 16580802
    [Abstract] [Full Text] [Related]

  • 13. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
    Wilcox M, Nathwani D, Dryden M.
    J Antimicrob Chemother; 2004 Feb 22; 53(2):335-44. PubMed ID: 14729745
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program.
    Williams DN, Bosch D, Boots J, Schneider J.
    Clin Ther; 1993 Feb 22; 15(1):169-79; discussion 168. PubMed ID: 8458046
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Roundtable discussion. Maximizing potential cost benefits of teicoplanin through appropriate usage.
    Rybak MJ, Allen R, Arnow P, Craven PC, Freeman R, Grüneberg RN, Korin J, Nightingale CH, Rubinstein E, Schaison GS.
    Hosp Formul; 1993 Jan 22; 28 Suppl 1():62-8. PubMed ID: 10123844
    [No Abstract] [Full Text] [Related]

  • 19. Cost analysis of a home intravenous antibiotic program.
    Chamberlain TM, Lehman ME, Groh MJ, Munroe WP, Reinders TP.
    Am J Hosp Pharm; 1988 Nov 22; 45(11):2341-5. PubMed ID: 3228090
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.